SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RxSight

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against RxSight, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements and undisclosed challenges affecting the company's performance [4][6]. Group 1: Legal Investigation and Class Action - The firm is encouraging investors who suffered losses exceeding $75,000 in RxSight between November 7, 2024, and July 8, 2025, to discuss their legal options [1]. - There is a deadline of September 22, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against RxSight [4]. - The complaint alleges that RxSight and its executives made false statements regarding the company's sales and utilization, overstated product demand, and failed to meet previously issued financial guidance for fiscal year 2025 [6]. Group 2: Financial Performance and Stock Impact - On July 8, 2025, RxSight reported preliminary second quarter 2025 financial results, indicating significant declines in LDD sales, LAL utilization, and overall revenue, leading to a lowered full-year guidance by approximately $42.5 million at the midpoint [7]. - Following the announcement, RxSight's stock price fell by $4.84, or 37.8%, closing at $7.95 per share on July 9, 2025, with unusually heavy trading volume [7].